[18F]PSMA-1007
Ligand of imaging of PSMA expression in vivo
- Localisation of lesions of prostate cancer
[18F]FMISO
[18F]Fluoromisonidazole
Imaging of hypoxia in vivo
- Assessment of tumor hypoxia as feature associated with therapeutic resistance
- PET-guided radiotherapy
- Evaluation of therapeutic response to antiangiogenic agents
[18F]Flumazenil
Imaging of GABA(A) receptors in vivo
- Presurgical evaluation of temporal lobe epilepsy
- Imaging the ischemic penumbra and assessment of therapeutic response
[18F]Fallypride
Imaging of D2/D3 receptors in vivo
- Differential diagnosis of idiopathic parkinsonian syndrome (IPS, Parkinson’s disease) and atypical parkinsonian syndrome (APS)
- Dose-finding PET occupancy studies of novel antipsychotics
[18F]FLT
[18F]3-deoxy-3-fluorothymidine
Imaging of cell proliferation in vivo
- Pretherapeutic prognostic assessment
- Evaluation of response to antitumour treatment
[18F]FES
[18F]Fluoroestradiol
Imaging of estrogen receptors in vivo
- Predictive imaging of response to endocrine therapy in women with oestrogen receptor positive breast cancer
- Detection of lesions of breast cancer when antioestrogene treatment is a therapeutic option
[18F]Mefway
Imaging of 5-HT1A receptors in vivo
- Imaging of 5-HT1A receptors in anxiety disorders and depression
- Drug development: Occupancy of agonist drugs at the 5-HT1A receptor
[68Ga]Nodaga-RGD
Ligand of integrin αv β3 for imaging of angiogenesis in vivo
- Prediction of therapeutic response to therapeutic regimens including medicines with antiangiogenic effect
[68Ga]PSMA-11
Ligand of imaging of PSMA expression in vivo
- Localisation of lesions of prostate cancer
[68Ga]DOTA-NOC
[68Ga]DOTA-1-Nal3-octreotide
Imaging of somatostatin receptors in vivo
- Characterisation, localisation, staging and restating of gastroenteropancreatic neuroendocrine tumours
- Detection of the primary occult neuroendocrine tumor when a metastasis of primary neuroendocrine tumor has been demonstrated or when the serum concentration of specific marker is increased